- Company
- Sputnik V's lot release is imminent
- by Kim, Jin-Gu Sep 2, 2021 05:59am
- The Russian COVID vaccine Sputnik V is about to be released, Korus Pharm said on Tuesday. According to Korus Pharm, local administrative procedures for Sputnik V's lot release are being finalized. The production of finished products with a capacity of 1000L has already been completed, and it is expected that the product will be released in
- Company
- SK Bioscience has started clinical trial of GBP510
- by Chon, Seung-Hyun Sep 2, 2021 05:59am
- Phase 3 of COVID vaccine developed in Korea have begun in earnest. SK Bioscience announced on the 30th that it has started administering the first subjects of phase 3 clinical trials of GBP510, jointly developed by the Institute for Protein Design (IPD) at the University of Washington. This is the first phase 3 clinical trial of a candidate subs
- Company
- It is necessary to provide Kymriah treatment accessibility
- by Sep 2, 2021 05:59am
- Novartis Korea (CEO Kim Skafte Mortensen) announced on the 30th that the ICBMT released the results of a study that analyzed the treatment of DLBCL patients in Korea from August 26 at ICBMT. DLBCL is an aggressive lymphoma that accounts for about 40% of non-Hodgkin lymphoma. Although most standard treatments show abnormalities in part, it
- Company
- ‘Somavert’ is reimbursed and starts landing in GHs
- by Eo, Yun-Ho Sep 1, 2021 05:57am
- The new acromegaly drug ‘Somavert’ was listed for insurance benefit and has begun landing in general hospitals. According to industry sources, Pfizer Korea’s Somavert (pegvisomant) has submitted landing applications to drug committees at major medical institutions including the Seoul National University Hospital, Severance Hospital, a
- Company
- Sales of PARP inhibitor Zejula surpassed Lynparza in 2 years
- by Sep 1, 2021 05:56am
- PARP inhibitor Zejula (Niraparib tosylate monohydrate) outpaced its competitor Lynparza (Olaparib) in about 2 years. According to IQVIA, a pharmaceutical market research firm on the 31st, Zejula, Takeda's ovarian cancer treatment drug, recorded ￦3.5 billion in sales in the second quarter, surpassing Lynparza, which recorded ￦3.4 billion.
- Company
- GS Cross’s Neulapeg sales jump fivefold in 3 years
- by An, Kyung-Jin Aug 31, 2021 06:14am
- The locally developed neutropenia treatment ‘Neulapeg’ is enjoying its belated prime. The drug, which was unable to make a presence earlier at the time of its release is continuing to break new records every quarter since signing a sales partnership with Boryung Pharmaceuticals. Neulapeg’s quarterly sales have risen over fivefold in the past
- Company
- Dong-A strengthens line-up with Sanofi's Actonel sales
- by Aug 31, 2021 06:13am
- Dong-A ST is expected to create synergy with its item Teribone by taking charge of the sale of Sanofi's osteoporosis treatment, Actonel. Dong-A ST will supply Sanofi-Aventis' osteoporosis treatment, Actonel, starting in October. Actonel is a bisphosphonate-based treatment that inhibits bone absorption. Since its launch in 2003, it has ran
- Company
- A lawsuit is scheduled to be filed against the price system
- by Nho, Byung Chul Aug 30, 2021 05:55am
- It is expected that a number of domestic and foreign pharmaceutical companies will file an administrative lawsuit to defend the lowering of the drug price due to the change in the drug price system. Due to the revaluation of the drug price system, 475 items will be reduced in batches starting next month, and the annual economic loss of pha
- Company
- Entry of generics halt Nexavar’s sole lead in liver cancer
- by Kim, Jin-Gu Aug 30, 2021 05:55am
- Nexavar (sorafenib), which had been leading the liver cancer treatment market for over 10 years since its launch, has handed over its lead to ‘Lenvima (lenvatinib)’. This was a combined result of Nexavar’s drug price falling 30% due to the launch of its generics, and the rise in sales of its competitor Lenvima. Nexavar’s position in
- Company
- Cosentyx begins competition in the market
- by Aug 30, 2021 05:54am
- As Interleukin-17 (IL-17) sanctions enter the primary biological formulation benefit range for psoriasis arthritis, they will compete in earnest with TNF-α inhibitors. Cosentyx (Secukinumab) of Novartis expanded health insurance benefits from psoriasis arthritis to primary biological sanctions on the 1st. Cosentyx can be used if it meets c
